跳转至内容
Merck
CN
所有图片(1)

文件

AB16955

Sigma-Aldrich

Anti-DR4 Antibody, CT

Chemicon®, from rabbit

登录查看公司和协议定价

别名:
TRAIL-R1
UNSPSC代码:
12352203
eCl@ss:
32160702
NACRES:
NA.41

生物来源

rabbit

质量水平

抗体形式

affinity purified immunoglobulin

抗体产品类型

primary antibodies

克隆

polyclonal

种属反应性

human

制造商/商品名称

Chemicon®

技术

western blot: suitable

NCBI登记号

UniProt登记号

运输

wet ice

靶向翻译后修饰

unmodified

基因信息

特异性

Apoptosis, or programmed cell death, occurs during normal cellular diffferentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand of the TNF family through their death domain containing receptors, TNFR1 and Fas. A novel cell death receptor was recently identified by several groups independently and designated DR4 (for death receptor 4) (Pan et al. 1997). The ligand for this novel cell death receptor has been identified and termed TRAIL, which is a new member in TRF family. Therefore, DR4 is also called TRAIL receptor-1 (TRAIL-R1) (Schneider et al. 1997). DR4 is expresssed in most of human tissues including spleen, peripheral blood leukocytes, small intestine and thymus. Like TNFR1, Fas and DR3, DR4 mediates TRAIL induced apoptosis and NF-kB activation in many tissues and cells.

免疫原

Epitope: C-terminus
Polyclonal antibody raised against a peptide corresponding to amino acids 427-445 at C-terminus of human DR4 mature protein.

应用

Detect DR4 using this Anti-DR4 Antibody, C-terminus validated for use in WB.
Research Category
Apoptosis & Cancer
Research Sub Category
Apoptosis - Additional
Western blot: 1:500-1:1000

Whole cell lysate from HeLa cells can be used as a positive control and a 57 kDa band should be detected.

Optimal working dilutions must be determined by end user.

外形

Affinity purified immunoglobulin. Liquid in PBS containing 0.02% sodium azide.
Format: Purified

储存及稳定性

Maintain refrigerated at 2-8°C in undiluted aliquots for up to 12 months.

其他说明

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

法律信息

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

免责声明

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

V Pavet et al.
Cell death & disease, 5, e1043-e1043 (2014-02-01)
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/TNFSF10/Apo2L) holds promise for cancer therapy as it induces apoptosis in a large variety of cancer cells while exerting negligible toxicity in normal ones. However, TRAIL can also induce proliferative and migratory signaling in cancer
Sofie Hagelund et al.
Frontiers in cell and developmental biology, 10, 768579-768579 (2022-03-15)
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an important mediator of tumor immune surveillance. In addition, its potential to kill cancer cells without harming healthy cells led to the development of TRAIL receptor agonists, which however did not show the
Dmitri V Rozanov et al.
Molecular cancer therapeutics, 8(6), 1515-1525 (2009-06-11)
Successful cancer therapies aim to induce selective apoptosis in neoplastic cells. The current suboptimal efficiency and selectivity drugs have therapeutic limitations and induce concomitant side effects. Recently, novel cancer therapies based on the use of tumor necrosis factor-related apoptosis-inducing ligand
Anna Willms et al.
PloS one, 14(4), e0214847-e0214847 (2019-04-05)
Due to their ability to preferentially induce cell death in tumor cells, while sparing healthy cells, TNF-related apoptosis-inducing ligand (TRAIL) and agonistic anti-TRAIL-R1 or anti-TRAIL-R2-specific antibodies are under clinical investigations for cancer-treatment. However, TRAIL-Rs may also induce signaling pathways, which
Florent Dufour et al.
Oncotarget, 8(6), 9974-9985 (2017-01-01)
TRAIL induces selective tumor cell death through TRAIL-R1 and TRAIL-R2. Despite the fact that these receptors share high structural homologies, induction of apoptosis upon ER stress, cell autonomous motility and invasion have solely been described to occur through TRAIL-R2. Using

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门